You can buy or sell Histogenics and other stocks, options, ETFs, and crypto commission-free!
Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. Read More The company was founded on June 28, 2000 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Advertising and Marketing
Yahoo FinanceApr 30
How Will Histogenics Shareholders Fare in the Merger with Ocugen
NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX), a clinical-stage company, focuses on the development of restorative cell therapies.
-$0.01 per share
Expected May 28, Pre-Market